Table 1.
Patient characteristics
| All patients analyzed for IDH(N = 4930) | |
|---|---|
| Age, median (IQR), y | 56 (45-66) |
| Female sex | 2429/4930 (49.3) |
| Disease status | |
| De novo | 3988/4891 (81.5) |
| Secondary AML | 626/4891 (12.8) |
| tMN | 277/4891 (5.7) |
| WBC count, median (IQR), (×109/L) | 14.7 (3.6-49.4) |
| Platelets, median (IQR), (×109/L) | 53 (29-99) |
| Bone marrow blasts, median (IQR), % | 65 (42-81) |
| Normal karyotype | 2539/4613 (55) |
| Complex karyotype | 452/3626 (12.5) |
| Trisomy 8 | 387/4613 (8.4) |
| ELN 2017 risk | |
| Favorable | 1578/4515 (35) |
| Intermediate | 1628/4515 (36.1) |
| Adverse | 1309/4515 (29) |
| NPM1 mutated | 1545/4895 (31.6) |
| FLT3-ITD mutated | 1088/4910 (22.2) |
| CEBPA mutated | 324/4862 (6.7) |
| Monoallelic | 108 (45.8) |
| Biallelic | 128 (54.2) |
| IDH1 mutated | 423/4930 (8.6) |
| IDH2 mutated | 575/4930 (11.7) |
| IDH1 and IDH2 mutated | 14/4930 (0.3) |
| IDH VAF, median (IQR) | 38.3 (30-43.3) |
| IDH1 mutation type | |
| R132C | 179/423 (42.3) |
| R132G | 28/423 (6.6) |
| R132H | 177/423 (41.8) |
| R132L | 18/423 (4.3) |
| R132S | 20/423 (4.7) |
| IDH2 mutation type | |
| R140G | 4/572 (0.7) |
| R140L | 8/572 (1.4) |
| R140Q | 438/572 (76.6) |
| R172K | 110/572 (19.2) |
| R172S | 1/572 (0.2) |
Data are presented as n/N (%) unless otherwise indicated.
IQR, interquartile range; ITD, internal tandem duplication; tMN, therapy-associated myeloid neoplasm; VAF, variant allele fraction.